XML 52 R41.htm IDEA: XBRL DOCUMENT v3.4.0.3
Basis of Presentation and Summary of Significant Accounting Policies - Concentrations and Significant Customer Information (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Dec. 31, 2014
Concentrations and Significant Customer Information        
Cash, cash equivalents and investments $ 480,200      
Investment in institutional money market funds 36,300      
Cash and cash equivalents $ 203,389 $ 243,801 $ 228,705 $ 119,296
Minimum        
Concentrations and Significant Customer Information        
Concentration risk (as a percent) 10.00% 10.00%    
Sales Revenue, Net | Customer Concentration Risk | Amerisource Bergen Drug Corporation        
Concentrations and Significant Customer Information        
Concentration risk (as a percent) 24.00% 30.00%    
Sales Revenue, Net | Customer Concentration Risk | McKesson Corporation        
Concentrations and Significant Customer Information        
Concentration risk (as a percent) 10.00% 10.00%    
Sales Revenue, Net | Customer Concentration Risk | Takeda Pharmaceutical Company Limited        
Concentrations and Significant Customer Information        
Concentration risk (as a percent)   13.00%    
Sales Revenue, Net | Customer Concentration Risk | Group Purchasing Organization        
Concentrations and Significant Customer Information        
Concentration risk (as a percent) 28.00% 23.00%    
Sales Revenue, Net | Geographic Concentration Risk        
Concentrations and Significant Customer Information        
Approximate percentage of revenues from customers outside the U.S.   13.00%    
Accounts Receivable | Credit Concentration Risk | Amerisource Bergen Drug Corporation        
Concentrations and Significant Customer Information        
Concentration risk (as a percent) 36.00%   43.00%